Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global CINVT Market Portraiture
2.2. Global CINVT Market, by Class, 2017 (US$ Mn)
2.3. Global CINVT Market, by Geography, 2017 (US$ Mn)
Chapter 3. Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global CINVT Market, by Key Players, 2017
Chapter 4. Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market, by Drug Class
4.1. Overview
4.2. Serotonin Receptor Antagonist
4.2.1. Ondansetron
4.2.2. Granisetron
4.2.3. Dolasetron
4.2.4. Palonosetron
4.3. Neurokinin NK1 Receptor Antagonist
4.3.1. Aprepitant
4.3.2. Casopitant
4.3.3. Netupitant
4.4. Dopamine Antagonist
4.4.1. Metoclopramide
4.4.2. Prochlorperazine
4.5. Benzodiazepine
4.5.1. Lorazepam
4.6. Others (Corticosteroids, Cannabinoids)
Chapter 5. Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market, by Geography
5.1. Overview
5.2. North America CINVT Market Analysis, 2016 – 2026
5.2.1. North America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.2.2. North America CINVT Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe CINVT Market Analysis, 2016 – 2026
5.3.1. Europe CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.3.2. Europe CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market Analysis, 2016 – 2026
5.4.1. Asia Pacific CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of Asia Pacific
5.5. Latin America CINVT Market Analysis, 2016 – 2026
5.5.1. Latin America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.5.2. Latin America CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa CINVT Market Analysis, 2016 – 2026
5.6.1. MEA CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
5.6.2. MEA CINVT Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA
Chapter 6. Company Profiles
6.1. Baxter Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Eisai, Inc.
6.3. Helsinn Healthcare
6.4. GlaxoSmithkline, Plc
6.5. Merck & Co. Inc.
6.6. ProStrakan, Inc.
6.7. Pfizer, Inc.
6.8. Sanofi-Aventis
6.9. Solvay Pharmaceuticals, Inc.
6.10. Teva Pharmaceutical Industries Ltd.
List of Figures
FIG. 1 Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market: Research Methodology
FIG. 2 CINVT Market Segmentation
FIG. 3 Global CINVT Market, by Drug Class, 2017 (US$ Mn)
FIG. 4 Global CINVT Market, by Geography, 2017 (US$ Mn)
FIG. 5 Attractive Investment Proposition: by Geography, 2017
FIG. 6 Competitive Analysis: Global CINVT Market, by Key Players, 2017
FIG. 7 Global Ondansetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 8 Global Granisetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 9 Global Dolasetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 10 Global Palonosetron Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 11 Global Aprepitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 12 Global Casopitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 13 Global Netupitant Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 14 Global Metoclopramide Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 15 Global Prochlorperazine Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 16 Global Lorazepam Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 17 Global Other Drug Class Market for Chemotherapy Induced Nausea and Vomiting Treatment, 2016 – 2026 (US$ Mn)
FIG. 18 U.S. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 19 Canada Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 U.K. Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 Germany Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 22 Rest of Europe Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 23 China Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 24 Japan Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 26 Brazil Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 27 Mexico Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 28 Rest of Latin America Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 29 GCC Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 30 Rest of Middle East and Africa Chemotherapy Induced Nausea and Vomiting Treatment Drugs Market, 2016 – 2026 (US$ Mn)
List of Tables
TABLE 1 Global Chemotherapy Induced Nausea and Vomiting Treatment (CINVT) Market Portraiture
TABLE 2 Global CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 3 Global Serotonin Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 4 Global Neurokinin NK1 Receptor Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 5 Global Dopamine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 6 Global Benzodiazepine Antagonist Market for Chemotherapy Induced Nausea and Vomiting Treatment, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 7 Global CINVT Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 8 North America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 9 North America CINVT Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 10 Europe CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 11 Europe CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Asia Pacific CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 13 Asia Pacific CINVT Market, by Country/Region, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 15 Latin America CINVT Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Middle East and Africa CINVT Market, by Drug Class, 2016 – 2026 (US$ Mn)
TABLE 17 Middle East and Africa CINVT Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 18 Baxter Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Eisai, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 Helsinn Healthcare: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 GlaxoSmithkline, Plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 ProStrakan, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Sanofi-Aventis: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Solvay Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)